Showing results (211-220 of 956) with videos related to
Sort By:
Pageof 96
Human Psychopharmacology|April 8, 2010
Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsideredIan Hindmarch, Kenji HashimotoThe Primary Care Companion for CNS Disorders|April 16, 2013
Beneficial effects of the sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: report of 5 casesYakup Albayrak, Kenji HashimotoAnnals of General Psychiatry|February 12, 2010
Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's diseaseTsutomu Furuse, Kenji HashimotoAnnals of General Psychiatry|June 25, 2010
Sigma-1 receptor agonist fluvoxamine for postoperative delirium in older adults: report of three casesTsutomu Furuse, Kenji HashimotoNeuron|July 21, 2022
The role of hippocampal KCNQ2 channel in antidepressant actions of ketamineLi Ma, Kenji HashimotoAnnals of General Psychiatry|April 27, 2010
Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five casesTsutomu Furuse, Kenji HashimotoExpert Review of Neurotherapeutics|December 5, 2018
An update on ketamine and its two enantiomers as rapid-acting antidepressantsKai Zhang, Kenji HashimotoThe International Journal of Neuropsychopharmacology|November 21, 2017
Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-KetamineYukihiko Shirayama, Kenji HashimotoBrain Research Bulletin|June 2, 2022
Special issue on "Brain-body communication in health and diseases"Kenji Hashimoto, Chun YangInternational Journal of Molecular Sciences|May 14, 2022
Soluble Epoxide Hydrolase as a Therapeutic Target for Neuropsychiatric DisordersJiajing Shan, Kenji HashimotoPageof 96